Format

Send to

Choose Destination
Ann Rheum Dis. 2020 Feb 17. pii: annrheumdis-2020-217018. doi: 10.1136/annrheumdis-2020-217018. [Epub ahead of print]

Rheumatic disorders associated with immune checkpoint inhibitors: what about myositis? An analysis of the WHO's adverse drug reactions database.

Author information

1
Department of Medical Pharmacology and Toxicology, University of Montpellier, Faculty of Medicine, Montpellier, Languedoc-Roussillon, France.
2
Department of Internal Medicine: Multi-Organic Diseases, Local Referral Center for Systemic Autoimmune Diseases, Montpellier University Hospital, University of Montpellier, Medical School, Montpellier cedex 5, France alexandremaria@hotmail.fr.
3
IRMB Institute for Regenerative Medicine and Biotherapy, INSERM U1183, University of Montpellier, Montpellier, France.
4
Department of Medical Oncology, Montpellier Cancer Institute, University of Montpellier, Faculty of Medicine, Montpellier, Languedoc-Roussillon, France.
5
Department of Dermatology, University of Montpellier, Faculty of Medicine, Montpellier, Languedoc-Roussillon, France.
6
Department of Neurology, University of Montpellier, Faculty of Medicine, Montpellier, Languedoc-Roussillon, France.
7
Department of Internal Medicine: Multi-Organic Diseases, Local Referral Center for Systemic Autoimmune Diseases, Montpellier University Hospital, University of Montpellier, Medical School, Montpellier cedex 5, France.
8
Department of Internal Medicine, Hopital Bicetre, Le Kremlin-Bicetre, France.
#
Contributed equally

KEYWORDS:

autoimmune diseases; dermatomyositis; epidemiology; polymyositis

Conflict of interest statement

Competing interests: ATJM has received fees from Abbvie, Actelion, CSL Behring, Experf, Novartis and Shire, and declares speaking fees from Astra-Zeneca and BMS in the last 5 years. PG is a medical expert for LFB (Laboratoire Français du Biofractionnement) and has received fees from Abbvie, Actelion, Boehringer Ingelheim France, Bouchara-Recordati, Novartis, Pfizer and Roche in the last 5 years. OL has received expert testimony and consultancy fees from BMS France, MSD, Astra Zeneca; consultancy fees from Genzyme, Incyte, and expert testimony for Janssen. Other authors declare that they have no conflicts of interest.

Publication type

Publication type

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center